Zoetis reaffirms full-year outlook amid weaker U.S. demand

Zoetis reaffirmed its full-year outlook despite weaker U.S. companion-animal demand and price cuts for Cerenia and Convenia amid generics. The company highlighted a pipeline targeting an estimated ~$3B renal market, diagnostics and biomarkers, and an oncology candidate with ~$1B potential.